Evidence map›Paper›PMID 35025062›Full record

ArticleDermatology and therapy2022

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Diamant Thaçi, Bruce Strober, Kenneth B Gordon, Peter Foley, Melinda Gooderham, Akimichi Morita, Kim A Papp, Lluís Puig, M Alan Menter, Matthew J Colombo and 8 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02931838 (A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis), which is not on this map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02931838 phase2completednot on this map

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis

TypeinterventionalSponsorBristol-Myers SquibbRan2016 to 2017Enrolled268ConditionsPsoriasisArmsBMS-986165, Placebo for BMS-986165
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.International journal of molecular sciences · 2023
    Review
  18. Review
  19. JAK Inhibitors in Psoriatic Disease.Clinical, cosmetic and investigational dermatology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 6 countries.

Diamant ThaçiInstitute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany. diamant.thaci@uksh.de.
Bruce StroberYale University, Central Connecticut Dermatology Research, New Haven, CT, USA.
Kenneth B GordonMedical College of Wisconsin, Milwaukee, WI, USA.
Peter FoleySt Vincent's Hospital Melbourne, Probity Medical Research, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia.
Melinda GooderhamSKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, ON, Canada.
Akimichi MoritaNagoya City University, Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Kim A PappClinical Research and Probity Medical Research, Waterloo, ON, Canada.
Lluís PuigHospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
M Alan MenterBaylor University Medical Center, Dallas, TX, USA.
Matthew J ColomboBristol Myers Squibb, Princeton, NJ, USA.
Yedid ElbezBristol Myers Squibb, Princeton, NJ, USA.
Renata M KisaBristol Myers Squibb, Princeton, NJ, USA.
June YeBristol Myers Squibb, Princeton, NJ, USA.
Andrew A NapoliBristol Myers Squibb, Princeton, NJ, USA.
Lan WeiBristol Myers Squibb, Princeton, NJ, USA.
Subhashis BanerjeeBristol Myers Squibb, Princeton, NJ, USA.
Joseph F MerolaHarvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Alice B GottliebIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Bristol-Myers Squibb (United States) · USProbity Medical Research · CABaylor University Medical Center · USHarvard University · USIcahn School of Medicine at Mount Sinai · USMedical College of Wisconsin · USNagoya City University · JPSt Vincent's Hospital · AUUniversitat Autònoma de Barcelona · ESUniversity of Lübeck · DEYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDeucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis.

methodsPost-hoc analysis of a 12-week Phase 2 trial was conducted for the three most efficacious dosage groups (3 mg twice daily, 6 mg twice daily, 12 mg once daily) and placebo. Investigator assessments for efficacy included Psoriasis Area and Severity Index (PASI), body surface area (BSA) involvement, and static Physician's Global Assessment; QoL was assessed using the Dermatology Life Quality Index (DLQI). Treatment responses and their associations were evaluated over time.

resultsDeucravacitinib elicited improvement versus placebo as early as Week 4 for most efficacy measures (including changes in absolute PASI and BSA), with efficacy trends observed from Week 2 to Week 12. Improvements in QoL, assessed by achievement of a DLQI overall score of 0/1 (no effect at all on patient's life), followed a pattern similar to deucravacitinib-related clinical outcomes over 12 weeks. Overall, patients with greater improvements in psoriasis-related clinical signs and symptoms also reported greater improvement in QoL. However, complete skin clearance was not required for achieving DLQI 0/1.

conclusionDeucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. Deucravacitinib has the potential to become a promising new oral therapy for this condition.

trial registrationClinicalTrials.gov identifier; NCT02931838.

Indexed as

Body surface areaHumansPsoriasisQuality of lifeTYK2

Identifiers

PMID35025062
PMCPMC8850503
OpenAlexW4205675137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.